Navigation Links
Isolagen, Inc. Reorganizes as Fibrocell Science, Inc.
Date:10/6/2009

fold wrinkles. Fibrocell Science, Inc. is planning to continue studies for additional aesthetic and therapeutic indications for azfibrocel-T.

About Fibrocell Science, Inc.

Fibrocell Science, Inc., (OTC Bulletin Board: FCSC) is a biotechnology company focused on developing regenerative fibroblast cells for aesthetic, medical and scientific applications. Fibrocell Science is committed to advancing the scientific, medical and commercial potential of autologous skin and tissue, as well its innovative cellular processing technology and manufacturing excellence. For additional information, please visit www.fibrocellscience.com.

Forward Looking Statements

All statements in this press release that are not based on historical fact are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include, without limitation, the timeliness of the target date for FDA response of January 4, 2010, the Company's ability to bring azfibrocel-T to market in 2010, and the Company's ability to hire a new chief executive officer in the near future. While management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of the Company's control, that could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth under Item 1A "Risk Factors" in the Com
'/>"/>

SOURCE Fibrocell Science, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Isolagen, Inc. Announces Receipt of Interim Order from Bankruptcy Court Approving DIP Motion
2. Isolagen, Inc. Receives Notification Letter from Amex
3. Isolagen, Inc. Reports Results of Shareholders Annual Meeting
4. ADM Reorganizes Operations
5. California Life Science, Business, and Economic Development Experts Discuss Californias Bioscience Future
6. FRC: NIH Stem Cell Guidelines Reflect Poor Science, Ignore Real Hope for Patients
7. Seahorse Bioscience, Inc. Acquires BioProcessors Corp.
8. Bert W. OMalley, M.D., Recipient of the 2008 National Medal for Science, Joins Bionovos Scientific Advisory Board
9. For creating new field of science, Texas chemist wins international prize
10. Todd R. Nelson Named Chief Executive Officer of eBioscience, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... 1, 2015 InferMed , ... will ... evidence-based clinical s olutions suite   ... information products and services, announced today the acquisition of  InferMed ... (CDS) technology company. InferMed,s Arezzo technology supports clinicians ...
(Date:7/1/2015)... NEW YORK , July 1, 2015 /PRNewswire/ ... G ), a global leader in designing, ... the Aecus Innovation Award in recognition of their ... operational efficiencies in UCB,s global business services (GBS) ... acknowledge service providers and clients that work together ...
(Date:6/30/2015)... 30, 2015 /PRNewswire/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) ... of Resverlogix have approved the resolutions relating to: ... of 5,600,000 units at a price of $2.67 ... being comprised of one common share and 0.075358 ... approximately CAD$15 million; and (ii) the amendment to ...
(Date:6/30/2015)... -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP ), a specialty ... unmet medical needs in women,s health, today announced ... at the Cantor Fitzgerald Inaugural Healthcare Conference as ... PM EDTLocation: , Le Parker Meridien Hotel, New ... under  ,Investor, or  click here The ...
Breaking Biology Technology:Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 2Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 2UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 3UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 5Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3Juniper Pharmaceuticals to Present at Cantor Fitzgerald Inaugural Healthcare Conference on July 8, 2015 2
... Life Sciences,Holdings, Inc. (Nasdaq: ADLS ), ... and commercialization of novel drugs in the,therapeutic ... today,announced that it was added to the ... reconstituted its comprehensive set of U.S. and,global ...
... 3 /Xinhua-PRNewswire-FirstCall/ -- Huifeng,Bio-Pharmaceutical Technology, Inc. (OTC ... of plant extracts and pharmaceutical raw materials,for ... in China,announced today that its company information ... Market Access Program, an information distribution,service that ...
... to offer choice of two distinct drugs on ... separate drug-eluting stent platforms, NATICK, ... today announced that the U.S. Food and Drug,Administration (FDA) has ... coronary artery disease. The,PROMUS Stent is a private-labeled XIENCE(TM) V ...
Cached Biology Technology:Advanced Life Sciences Added to Russell Microcap Index 2Advanced Life Sciences Added to Russell Microcap Index 3Huifeng Bio-Pharmaceutical (HFGB) Information to Be Available Through Standard & Poor's Market Access Program 2Boston Scientific Announces FDA Approval for PROMUS(TM) Everolimus-Eluting Coronary Stent System 2Boston Scientific Announces FDA Approval for PROMUS(TM) Everolimus-Eluting Coronary Stent System 3Boston Scientific Announces FDA Approval for PROMUS(TM) Everolimus-Eluting Coronary Stent System 4
(Date:6/17/2015)... and HILDEN, Germany , June 17, 2015 ... Frankfurt Prime Standard: QIA) today launched new Investigator ® ... laboratories in the United States . The ... analyze multiple key genomic markers (short tandem repeats or STRs) ... Sensor to evaluate the quality of DNA in each sample, ...
(Date:6/16/2015)... , June 16, 2015 Fingerprint Cards ... fingerprint sensors in the company,s portfolio from one of its ... planned to mainly take place during the third quarter 2015. ... Asia . Jörgen Lantto, CEO of ...   the   growing interest from smartphone OEMs in integrating ...
(Date:6/12/2015)... 12, 2015  Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring, announced the ... electronically capture, analyze and identify participants of a ... This system can: , ... and subsequent sign-on process is actually the person ...
Breaking Biology News(10 mins):QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5FPC Receives Order for Touch Fingerprint Sensors of 375 MSEK 2Securus Announces Patent Issued for Authorized Presence Verification During Video Visitation 2
... two genetic variants that increase the risk of developing ... to the origin of this often very painful condition, ... life of sufferers. Details of the research, ... Genetics and the Nuffield Department of Obstetrics & Gynaecology, ...
... Hospital (MGH) researchers has developed a faster way to ... inactivation, repair or alteration. The report from the ... Nature Methods , describes a highly effective but less ... (ZFNs). "With our approach, called context-dependent assembly, ...
... the University of California, Riverside have identified components in ... cells and weaken their attraction to a chemical signal ... bone. The research could lead to new therapies ... of Manuela Martins-Green , a professor of cell ...
Cached Biology News:Genetic variants linked to increased risk of common gynecological disease 2MGH researchers develop faster method of engineering zinc-finger nucleases 2MGH researchers develop faster method of engineering zinc-finger nucleases 3UCR scientists identify pomegranate juice components that could stop cancer from spreading 2
...
...
Contains L-glutamine...
... Anti-PRK2 MW 140kDa ... Immunogen Peptide spanning amino acids 926-941 ... immunoaffinity purified Quality Assurance ... lysates from HeLa cells. Stability ...
Biology Products: